Teprotumumab-trbw

Class: EENT Drugs, Miscellaneous
Chemical Name: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer
Molecular Formula: C₆₄₇₆H₁₀₀₁₂N₁₇₄₈O₂₀₀₀S₄₀
CAS Number: 1036734-93-6
Brands: Tepezza

Medically reviewed by Drugs.com on Feb 14, 2022. Written by ASHP.

Introduction

Teprotumumab-trbw, an anti-insulin-like growth factor-1 receptor (anti-IGF-1R) monoclonal antibody, reduces proptosis and diplopia in patients with thyroid eye disease.

Uses for Teprotumumab-trbw

Teprotumumab-trbw has the following uses:

Teprotumumab-trbw is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease.

Teprotumumab-trbw Dosage and Administration

General

Teprotumumab-trbw is available in the following dosage form(s) and strength(s):

For Injection: 500 mg lyophilized powder in a single-dose vial for reconstitution.

Dosage

It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

Dosage and Administration

• Initiate dosing with 10 mg/kg for first infusion, followed by 20 mg/kg every 3 weeks for 7 additional infusions.

• Administer teprotumumab-trbw by intravenous infusion over 60 to 90 minutes.

Cautions for Teprotumumab-trbw

Contraindications

None.

Warnings/Precautions

Infusion Reactions

Teprotumumab-trbw may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with teprotumumab-trbw. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during any of the infusions or within 1.5 hours after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids and antihistamines. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, and/or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Exacerbation of Preexisting Inflammatory Bowel Disease

Teprotumumab-trbw may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspe...